Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Carolina M. Reyes, PhD
Advertisement
Articles by Carolina M. Reyes, PhD
Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
Published: February 2nd 2011 | Updated:
- Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Published: November 13th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Celebrating the Pharmacist’s Impact: How Pharmacists Elevate Care in Every Setting
3
FDA Approves 1-Minute HIV Self-Test
4
How Pharmacists Can Navigate Legal Complexities With Most Favored Nation Status
5
